RxPG News Feed for RxPG News

Medical Research Health Special Topics World
 Asian Health
 Food & Nutrition
 Men's Health
 Mental Health
 Occupational Health
 Public Health
 Sleep Hygiene
 Women's Health
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 World Healthcare
   Latest Research
 Alternative Medicine
  Bone Cancer
  Breast Cancer
  Cervical Cancer
  Gastric Cancer
  Liver Cancer
  Nerve Tissue
  Ovarian Cancer
  Pancreatic Cancer
  Prostate Cancer
  Rectal Cancer
  Renal Cell Carcinoma
  Risk Factors
  Testicular Cancer
 Clinical Trials
 Infectious Diseases
 Sports Medicine
   Medical News
 Awards & Prizes
   Special Topics
 Odd Medical News

Last Updated: Oct 11, 2012 - 10:22:56 PM
NCCTG clinical trial N9831 Breast Cancer Channel

subscribe to Breast Cancer newsletter
Latest Research : Cancer : Breast Cancer

   EMAIL   |   PRINT
Safe side effect profile for HER-2 positive breast cancer patients using trastuzumab

Jun 6, 2006 - 1:29:00 AM , Reviewed by: Priya Saxena
"We hoped also to show that trastuzumab did not add complications to radiation treatment, and the current study has certainly proven that, providing good news for many women."

[RxPG] Researchers in the North Central Cancer Treatment Group (NCCTG) have shown that patients who receive trastuzumab at the same time as post-chemotherapy radiation treatments for HER-2 positive breast cancer have no more risk for major side effects or complications than those who do not receive the drug.

This study resulted from NCCTG clinical trial N9831, from which breakthrough treatment findings were presented at ASCO 2005. "The original N9831 study showed that trastuzumab reduced the recurrence of HER-2 positive breast cancer about 50 percent," says Dr. Halyard, a radiation oncologist at Mayo Clinic Arizona and lead author of today's study. "We hoped also to show that trastuzumab did not add complications to radiation treatment, and the current study has certainly proven that, providing good news for many women."

About 25 percent to 30 percent of breast cancers produce an overabundance of a growth-promoting protein called human epidermal growth factor receptor (HER-2). These tumors tend to grow faster and are generally more likely to recur than tumors that do not overproduce HER-2. Trastuzumab is the first identified monoclonal antibody designed specifically to attack this overexpressed protein, and is used as a follow-on treatment to chemotherapy. A monoclonal antibody is a laboratory-engineered protein that helps the body's immune system fight foreign invaders such as cancer.

Dr. Halyard's study looked at the side effects related to adding trastuzumab to radiation therapy. In the 1,460 patients who received radiation in the original N9831 group, there was no significant difference in the incidence of skin reactions, pneumonitis, dyspnea, cough, esophageal dysphagia or neutropenia between those who received trastuzumab (908), and those who did not (552). Additionally, the researchers report that within the group of 1,286 patients who received trastuzumab, those who had radiation (908) were no more likely to have cardiac complications than those who did not (378).

Publication: Mayo Clinic's Michele Halyard, M.D., presented these findings on June 5, at the 2006 American Society of Clinical Oncology (ASCO) annual meeting in Atlanta.
On the web: cancercenter.mayo.edu/mayo/research/womens_cancer 

Advertise in this space for $10 per month. Contact us today.

Related Breast Cancer News
Blood test predicts breast cancer recurrence
Interferon-stimulated gene 15 (ISG15), a ubiquitin like protein, is a new therapeutic target for breast cancer
Smoking may have an association with breast cancer in women
Vitamins and calcium supplements appear to reduce the risk of breast cancer
Acupuncture has added benefits in breast cancer patients
Study finds higher risk of cancer recurrence in women with dense breasts
Physical activity after menopause reduces breast cancer
Genes responsible for susceptibility to breast cancer metastasis can be inherited
Oestrogen therapy of benefit in some women with metastatic cancer
Awry protein linked to breast cancer

Subscribe to Breast Cancer Newsletter

Enter your email address:

 Additional information about the news article
The NCCTG trastuzumab trial was led by Mayo Clinic Jacksonville's Edith Perez, M.D., with Dr. Halyard as a co-investigator. It was a cooperative effort with the Eastern Cooperative Oncology Group (ECOG), the Southwest Oncology Group (SWOG), and the Cancer and Leukemia Group B (CALGB). Study co-investigators included Mayo Clinic Rochester's Thomas Pisansky, M.D.; and Amylou Dueck, Ph.D.; along with Lori Pierce, M.D., University of Michigan; Lawrence Solin, M.D., University of Pennsylvania; and Lawrence Marks, M.D., Duke University.

The study presented is one of several studies resulting from information gained in NCCTG clinical trial N9831. NCCTG is a national clinical research group sponsored by the National Cancer Institute. Research is based at Mayo Clinic. NCCTG consists of a network of cancer specialists at community clinics, hospitals and medical centers in the United States, Canada and Mexico. The group is dedicated to bringing clinical trials with promising new cancer therapies to communities where patients live.

Trastuzumab, trade name HerceptinĀ®, is manufactured by Genentech, which provided some support for this study, along with the National Institutes of Health and the Breast Cancer Research Foundation.

For more information on breast cancer research at Mayo Clinic, visit http://cancercenter.mayo.edu/mayo/research/womens_cancer. To find out more about NCCTG and available clinical trials, visit http://ncctg.
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

Contact us

RxPG Online



    Full Text RSS

Ā© All rights reserved by RxPG Medical Solutions Private Limited (India)